cardiovascular risks and mortality. 11 The European Society of Cardiology (ESC) and the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines/Heart Failure Society of America (ACC/AHA/HFSA) recommend using different treatment approaches for HF with reduced (rEF; EF <40%,), mid-range (mrEF; EF 40%-49%), and preserved (pEF; EF ≥50%) EF. 1, 9 However, HF diagnosis can be challenging, 12, 13 and the prognostic potential of EF appears to be reduced for values above 40% to 45%, 14, 15 thereby further complicating the diagnosis of HF for patients with mrEF or pEF. 1, 12, 13, 16 Moreover, the effectiveness of HF-approved therapies has mainly been demonstrated in rEF patients. 1 Thus, additional predictors are needed to more accurately stratify HF patients and improve clinical decision making.
B-type natriuretic peptide (BNP) is a peptide hormone that is now the gold standard diagnostic and prognostic biomarker for HF. 17 Indeed, a systematic review of 19 studies reported that, for every 100 pg/mL rise in BNP concentration, there is a corresponding 35%
increase in the risk of death, and recent updates of the ACC/ AHA/HFSA and ESC guidelines recommend using BNP levels in the risk stratification of HF. 1, 9 The use of BNP levels in stratifying HF patients is supported by three prospective studies, which collectively demonstrate that BNP levels correlate with EF, 18 and that the prognostic value of BNP is equal or even higher than that of EF. 19, 20 However, to the best of our knowledge, the clinical outcomes of HF patients stratified using EF or BNP levels have not been studied in a real-world setting. Furthermore, there are limited data pertaining to the use of BNP to predict events, such as AMI and ischemic stroke in patients with HF. In order to fill this knowledge gap, this US retrospective claims study was conducted to evaluate the association of cardiovascular events (ie, ischemic stroke, AMI) with EF levels and to assess the prognostic value of BNP in a real-world setting.
2 | METHODS to the index admission date were used to group patients. Stratifications by BNP levels were performed using median BNP levels as a cutoff between low and high BNP (L-and H-BNP, respectively) subgroups (BNP cutoff for: all patients = 411 pg/mL; EF < 40% = 644 pg/mL; EF 40%-50% = 534 pg/mL; EF ≥ 50% = 321 pg/mL).
| Data source

| Outcome definition
Study outcomes included a primary diagnosis of ischemic stroke or AMI resulting in hospitalization. All-cause mortality was also evaluated as a secondary outcome to account for the competing risk of death in patients with HF. The observation period was defined as the shortest time frame between the 1-year period following the index date and the period spanning from the index date up to the earliest date among end of data availability (September 30, 2016), end of insurance coverage, or death. Of note, for the all-cause mortality analyses, the end of the eligibility period was used as a proxy of the date of death in patients indicated as deceased but without an associated date of death. More specifically, in these patients, the date of death was defined as the last day of the month during which end of eligibility occurred.
| Sensitivity analyses
Sensitivity analyses were performed for HF patients diagnosed with 
| Statistical analysis
Baseline characteristics were evaluated using means, medians, and standard deviations (SDs) for continuous variables, and using frequencies and percentages for categorical variables. Kaplan-Meier (KM) rates and log-rank tests evaluated during the observation period were used to compare the cumulative incidence of study outcomes 
| Outcomes of patients stratified by BNP levels (N = 2456)
Independently of EF levels, H-BNP was not significantly associated with higher risks of ischemic stroke and AMI compared to L-BNP (Table 2) . However, H-BNP patients had significantly higher risks of 3.9 ± 1.9 [4] 3.4 ± 1.9 [3] 3.6 ± 1.9 [4] 3.2 ± 2.0 [3] 3.8 ± 1.8 [4] 4.1 ± 1.7 [4] 3.6 ± 1.9 [4] 4.1 ± 1.8 [4] 4.5 ± 1.7 [4] 3.9 ± 1. all-cause mortality than L-BNP patients (ie, HR = 1.40, P < 0.001; Table 2 ).
| Outcomes of patients stratified by EF and BNP levels (N = 2456)
Among rEF patients, the risk of ischemic stroke was significantly higher for H-BNP patients compared to L-BNP patients (ie, HR = 5.03, P = 0.013; Table 2 ). Although the risk of ischemic stroke was numerically higher among pEF and mrEF patients with H-BNP, the differences did not reach statistical significance (Ps > 0.05; Table 2 ). In both the rEF and pEF cohorts, all-cause mortality was significantly higher for H-BNP patients compared to L-BNP patients (ie, pEF mortality: HR = 1.48, P = 0.001; Table 2 ).
| CAD and diabetes subgroups
In 
| DISCUSSION
Here, the association between HF clinical outcomes vs EF and BNP levels was investigated, and the prognosis of patients stratified by these variables was evaluated. HF patients with rEF had a significantly to 45%, 14 which further complicates clinical decisions for these patients. The results presented in the present study contribute to documenting the prognosis of mrEF patients. Indeed, mrEF patients were found to have a higher risk of AMI compared to patients with pEF, but no such difference was observed when comparing the risk of ischemic stroke between these two cohorts, which might be attributed to the limited predictive power of EF for these EF values.
14,15
The ESC guidelines also highlight challenges inherent to the diagnosis and treatment of HF patients with pEF. 1 It has been reported that the prevalence of HF with pEF is substantial (~50%) and seemingly increases over time. 26 Thus, predictors other than EF may be instrumental to help physicians make informed clinical decisions for this population as well. In line with this concept, BNP levels were found to be significant predictors of mortality in the present study.
However, neither the risk of stroke nor that of AMI were significantly different when comparing H-BNP and L-BNP patients. This might be in part attributable to the smaller sample sizes for analyses performed with a BNP-based stratification compared to those performed with an EF-based stratification, although other factors may contribute. Interestingly, comparing stroke and AMI risk across all EF cohorts among patients also diagnosed with diabetes or CAD revealed trends that were very similar to those observed in the overall HF population, suggesting that conclusions on the prognostic value of EF hold true for these patients. In addition, as might be expected, the rates of AMI appeared higher in patients with CAD compared with the overall population, although no statistical test was performed. This might indicate that patients with CAD and HF (HF/CAD) have unmet needs that are not addressed by the current medications.
The most recent guidelines do not endorse anticoagulation treatment in HF 1,9 largely because of disappointing results from clinical trials that assessed the efficacy and safety profile of warfarin vs aspirin, [27] [28] [29] [30] although these data remain controversial. 31 To date, the use of non-vitamin K oral antagonist (NOACs) is only approved for HF patients also diagnosed with AF, but the impact of NOACs on HF patients who also suffer from other cardiovascular conditions, such as CAD, remains unknown. The data from the present study suggest that a High and low BNP determined using the median as cutoff (all = 411 pg/mL; EF < 40% = 644 pg/mL; EF 40%-50% = 534 pg/mL; EF ≥ 50% = 321 pg/mL). b The end of the eligibility period was termed the death date if a patient was indicated deceased without an associated date.
HF patients without AF also have unmet needs, which may help in guiding the design of future studies and trials.
| Limitations
The present study is subject to a number of limitations. First, due to the inherent nature of insurance claims databases, coding inaccuracies or omissions in procedures and diagnoses could have occurred. Second, despite adjusting for many baseline covariates, the impact of unmeasured confounders cannot be ruled out. Third, this analysis does not differentiate between the etiologies and heterogeneity of HF, which could play a role in the clinical outcomes and patient care.
Fourth, although the closest value to the index date was used to define EF, this measure was allowed to be recorded up to 90 days before or after the index date, a time frame during which EF may vary.
Similarly, the most recent BNP value prior to discharge date of the index hospitalization or ER was used, however, BNP measures could also vary throughout the same hospitalization or ER visit. Finally, the requirement for diagnostic tests like EF and/or BNP may lead to a selection bias for patients with characteristics that may be different from the overall population of patients with HF.
| CONCLUSION
The prognostic value of EF and BNP levels among HF patients remains understudied in the real world. In this retrospective cohort study that used data from a large US insurance claims database, HF patients with rEF were found to have significantly worse clinical outcomes compared to patients with pEF, thereby confirming the reliability of EF in this subpopulation. BNP levels were also a reliable predictor of mortality. Moreover, the prognosis of rEF patients was significantly worse among those who had high BNP levels with respect to stroke risk, and mortality. The present work also contributes to documenting the prognosis of mrEF patients, who were found to have a higher risk of AMI vs pEF patients. This study is the first to show the real-world association of EF and BNP with clinical outcomes, further supporting the recommendation to use these markers in clinical practice. These results may help guide future recommendations and improve the clinical management of HF.
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